Search
ChatPaper
AI Writing
analysis
Analysis
编组
Open Data
more
More
RankingsMust ReadingJournal&ConferenceAI TRAI HistoryMaster Reading TreeXiaomai's Star TalentsTrajectoryTalentNDI TrackerAI sign LanguageOpen
VIPCreated with Sketch.

Cost-Effectiveness Analysis of Pembrolizumab as an Adjuvant Treatment of Renal Cell Carcinoma Post-nephrectomy in the United States.

Yizhen Lai,Arielle G Bensimon, Emily Gao,Rituparna Bhattacharya,Ruifeng Xu,Jestinah Chevure,Kentaro Imai,Naomi B Haas

Clinical genitourinary cancer（2023）

Cited 0|Views3
No score
Abstract
Pembrolizumab is projected to be cost-effective as an adjuvant RCC treatment versus routine surveillance or sunitinib based on a typical willingness-to-pay threshold.
More
Translated text
Key words
renal cell carcinoma,cost-effectiveness cost-effectiveness,pembrolizumab,adjuvant treatment,post-nephrectomy
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined